At BIO-Europe 2025 in Vienna, ReNewVax CEO Neil Murray sat down with BiotechTV’s Amy Brown to share how the company is advancing a next-generation, low-cost universal pneumococcal vaccine, targeting all 100 known serotypes of Streptococcus pneumoniae.
“We’re confident that we’ve got the first low-cost universal pneumococcal vaccine,” said Neil during the interview, highlighting the urgent need for broader, more durable protection than what current vaccines offer.
In the discussion, Neil outlined how ReNewVax’s proprietary antigen discovery platform is addressing a significant gap in the market, one that current pneumococcal vaccines have yet to fill, by using genomics and rational design to develop a vaccine with global accessibility and long-term efficacy.
He also spoke openly about the company’s plans to secure a lead investor for its upcoming Series A funding that will support first-in-human clinical trials of RVX-001 and advance additional pipeline programs focused on AMR-related bacterial infections.
At ReNewVax, we’re committed to tackling antimicrobial resistance (AMR) and protecting global health with innovative, scalable vaccine solutions.
Watch the full interview here:
BiotechTV – Neil Murray at BIO-Europe 2025
Or here is a quick snippet: